UK MHRA Aligns with INmune Bio on Ebstrocel Conditional MAA, Paving Way for 2026 Submission
Summary
INmune Bio received positive alignment from the UK's MHRA for its planned 2026 conditional Marketing Authorization Application (MAA) for Ebstrocel (CORDStrom™) in RDEB. The MHRA confirmed agreement on CMC, non-clinical, and clinical evidence packages, providing a clear regulatory path. This news follows an 8-K filed minutes earlier today disclosing the same positive regulatory feedback. This is a crucial step towards potential commercialization in the UK for Ebstrocel, offering a clearer path to market for one of its key drug candidates. For a small biotech company with a going concern warning, securing regulatory alignment significantly de-risks the development pathway and provides a potential revenue stream. The company plans to submit the conditional MAA in 2026.
At the time of this announcement, INMB was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.8M. The 52-week trading range was $1.09 to $11.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.